Laparoscopic Surgery of Pancreatic Endocrine Tumors: Is There a Benefit? Abstract #379

Introduction: Minimally invasive surgery is widely adopted for the treatment of surgical diseases, but results of laparoscopic procedures for pancreatic endocrine tumors (PET) are published in small series.
Aim(s): To reveal and estimate the benefits of laparoscopic resection of PET and to compare it with the open approach by reviewing the available data.
Materials and methods: Medline search for the words laparoscopic resection and pancreatic endocrine tumors was performed. Fifty-two relevant papers were identified and studied in the period 2000-2011.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Markiyan Soloviy
Authors: Soloviy M

To read results and conclusion, please login ...

Further abstracts you may be interested in

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#31 Patterns and predictors of failure after curative resections of pancreatic endocrine carcinoma
Introduction: Pancreatic endocrine carcinomas (PECs) are generally associated with a good prognosis, above all after radical resection. In other pancreatic malignancies, predictors of failure and the role of lymph node ratio (LNR) are well-known, but prognostic factors and the value of LNR, as well as patterns of recurrence after surgery for PEC has never been investigated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Massimo Falconi
#32 Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior.
Introduction: Cystic pancreatic endocrine tumors (CPETs) are rare lesions and their biological features have been scarcely investigated.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Massimo Falconi